TCRX — Tscan Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $90.55m
- -$167.49m
- $2.82m
Annual income statement for Tscan Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.08 | 10.1 | 13.5 | 21 | 2.82 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 27.3 | 58.8 | 80.2 | 115 | 139 |
| Operating Profit | -26.2 | -48.6 | -66.6 | -93.5 | -136 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -26.1 | -48.6 | -66.2 | -89.2 | -127 |
| Net Income After Taxes | -26.1 | -48.6 | -66.2 | -89.2 | -127 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -26.1 | -48.6 | -66.2 | -89.2 | -127 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -26.1 | -48.6 | -66.2 | -89.2 | -127 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.11 | -2.06 | -2.75 | -1.36 | -1.13 |
| Dividends per Share |